Free Trial
NASDAQ:GANX

Gain Therapeutics Q2 2025 Earnings Report

Gain Therapeutics logo
$1.58 -0.03 (-1.55%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.57 -0.01 (-0.95%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

Gain Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Gain Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Gain Therapeutics Earnings Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Gain Therapeutics Announces Proposed Public Offering
See More Gain Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gain Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gain Therapeutics and other key companies, straight to your email.

About Gain Therapeutics

Gain Therapeutics (NASDAQ:GANX) is a clinical-stage biotechnology company dedicated to discovering and developing novel small-molecule therapies targeting protein misfolding and aggregation pathways. Utilizing a proprietary structure-based drug discovery engine, the company focuses on identifying allosteric sites that modulate protein function, with the aim of delivering first-in-class treatments for rare neurodegenerative disorders. Its research framework leverages advanced computational modeling and high-throughput screening to accelerate the design of molecule candidates with optimized efficacy and safety profiles.

The company’s core discovery platform integrates artificial intelligence, molecular dynamics simulations and crystallography data to pinpoint cryptic binding pockets on disease-relevant proteins. This approach enables Gain Therapeutics to generate highly selective modulators that correct dysfunctional protein behavior rather than simply inhibiting activity. By exploiting allosteric mechanisms, the pipeline seeks to minimize off-target effects and overcome challenges associated with more conventional drug discovery modalities.

Gain Therapeutics’ lead program is advancing a small-molecule therapeutic for GM2 gangliosidosis, encompassing Tay-Sachs and Sandhoff diseases. Preclinical studies have demonstrated promising pharmacodynamic and pharmacokinetic profiles, paving the way for clinical evaluation. Beyond GM2 gangliosidosis, the company is exploring additional neurometabolic and neurodegenerative targets, including Parkinson’s disease and lysosomal storage disorders. Collaborations with academic institutions and patient advocacy groups support its translational efforts and help inform clinical trial design.

Founded in 2018 and headquartered in Zug, Switzerland, Gain Therapeutics maintains research operations in North America and Europe. The company is led by CEO Andrea Piumatti, whose background spans biotech leadership and drug development, alongside a management team with extensive experience in medicinal chemistry, computational biology and clinical research. Guided by a board of directors comprising seasoned industry executives and scientific advisors, Gain Therapeutics is positioned to advance its innovative platform toward delivering transformative treatments for patients with underserved neurological conditions.

View Gain Therapeutics Profile

More Earnings Resources from MarketBeat